Arrivo Bio has announced a significant advancement in the fight against major depressive disorder (MDD) by initiating dosing for the first patient in the SP-624-202 clinical trial.

This Phase 2b study aims to enroll 450 participants with MDD to evaluate the effectiveness of SP-624, a SIRT6 activator with a novel mechanism of action, compared to a placebo in treating adults with MDD. The primary endpoint of the SP-624-202 study will be the change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS), commonly used in clinical trials. The study will also explore various other endpoints rated by both investigators and patients, as well as investigate biomarkers for further insights.

SIRT6 is an enzyme crucial for human health, contributing to gene expression regulation, mitochondrial health, and DNA repair. It has potential applications in addressing aging-related diseases, neurodegeneration, diabetes, obesity, and depression. Arrivo is exploring SP-624's potential in multiple therapeutic areas beyond depression.

Dr. Joel Raskin, Chief Medical Advisor at Arrivo, expressed excitement about the study's initiation, highlighting the persistent challenges faced by individuals with MDD and the potential of SP-624 to offer transformative outcomes with fewer side effects.

Arrivo is committed to pioneering research in MDD and looks forward to sharing further progress from the SP-624-202 study.

 

Source: businesswire.com

Report Abuse